Valuation: Glaukos Corporation

Market Cap 8.97B 7.84B 7.23B 6.68B 12.68B 855B 12.89B 86.43B 33.94B 421B 33.66B 32.93B 1,448B P/E 2026 *
-162x
P/E 2027 * 968x
Enterprise Value 8.76B 7.66B 7.07B 6.53B 12.38B 835B 12.59B 84.42B 33.15B 411B 32.88B 32.17B 1,415B EV / Sales 2026 *
13.9x
EV / Sales 2027 * 10.9x
Free-Float
96.33%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week+2.95%
Current month+9.27%
1 month+22.90%
3 months+31.20%
6 months+35.25%
Current year+35.26%
1 week 143.11
Extreme 143.11
156.6
1 month 125.43
Extreme 125.43
156.6
Current year 93.96
Extreme 93.96
156.6
1 year 73.16
Extreme 73.16
156.6
3 years 59.22
Extreme 59.22
163.71
5 years 33.33
Extreme 33.33
163.71
10 years 23.08
Extreme 23.075
163.71
Manager TitleAgeSince
Chief Executive Officer 65 2000-12-31
Director of Finance/CFO 56 2022-03-31
President 50 2022-03-31
Director TitleAgeSince
Director/Board Member 67 2006-12-31
Director/Board Member 71 2014-06-30
Director/Board Member 57 2014-06-30
Date Insider Type Main position Quantity % Market Cap.
07-05Fiscal year

Chief Financial Officer

30,000 0.0523%
06-30Sell

Executive/Senior Manager

-716 0.0012%
06-24Tax

Executive/Senior Manager

-483 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%+2.95%+47.11%+114.40% 8.97B
+0.82%+0.99%-15.32%+11.26% 126B
+0.84%+1.15%+1.56%-2.98% 12.9B
+4.14%-2.38%-48.62%-72.11% 3.98B
-0.47%-1.34%+20.55%+44.06% 2.7B
+0.61%-7.70%-14.75%-21.70% 1.74B
+0.49%-3.87%-6.10%-27.10% 1.61B
+0.47%+10.24%-60.26%-83.44% 1.49B
+2.10%+14.44%-24.33%-60.35% 1.48B
Average +0.83%+1.73%-11.13%-10.88% 17.92B
Weighted average by Cap. +0.75%+1.13%-11.12%+12.07%

Financials

2026 *2027 *
Net sales 630M 551M 509M 470M 891M 60.13B 906M 6.08B 2.39B 29.62B 2.37B 2.32B 102B 793M 694M 640M 591M 1.12B 75.63B 1.14B 7.64B 3B 37.26B 2.98B 2.91B 128B
Net income -56.38M -49.32M -45.49M -42.01M -79.72M -5.38B -81.06M -544M -213M -2.65B -212M -207M -9.11B 9.02M 7.89M 7.28M 6.72M 12.75M 860M 12.97M 86.95M 34.14M 424M 33.87M 33.13M 1.46B
Net Debt -208M -182M -168M -155M -294M -19.84B -299M -2.01B -788M -9.78B -781M -764M -33.61B -340M -297M -274M -253M -480M -32.41B -489M -3.28B -1.29B -15.96B -1.28B -1.25B -54.88B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
26-07-10 US$152.72 -1.52% 672,327
26-07-09 US$155.07 +1.38% 781,020
26-07-08 US$152.96 +1.53% 1,058,780
26-07-07 US$150.65 +1.31% 710,265
26-07-06 US$148.70 +0.24% 712,964
Trader
Investor
-
Global
-
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
152.72USD
Average target price
161.23USD
Spread / Average Target
+5.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock